Aligos Therapeutics, Inc. (ALGS) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 6.44 |
| Open | 6.48 |
| Day High | 6.73 |
| Day Low | 6.45 |
| 52-Week High | 13.69 |
| 52-Week Low | 3.98 |
| Volume | 28,285.5 |
| Average Volume | 180,441 |
| Market Cap | 41.4M |
| PE | -0.92 |
| EPS | -7.3 |
| Moving Average 50 Days | 5.63 |
| Moving Average 200 Days | 7.16 |
| Change | 0.25 |
Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026
GlobeNewswire Inc.
Feb 26, 2026 1:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, toda
Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI)
GlobeNewswire Inc.
Feb 23, 2026 1:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases,
Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates
GlobeNewswire Inc.
Jan 21, 2026 1:00 PM GMT
Interim analyses on track for the first and second half of 2026SOUTH SAN FRANCISCO, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes